Joint development and sales partnership with SCSK for an AI register
First written in FY2018-Q3. 3 of 6 entries say "Restated". Latest entry: FY2019.
No other company in this theme has enough history to compare yet.
- FY2019DroppedAnnual report
「The joint development agreement ended during the fiscal year under review upon expiration of the contract period.」
The company states that its agreement with SCSK Corporation for the joint development of AI technology and the grant of sales rights ended during the fiscal year under review upon expiration of the contract period. - FY2019-Q3RestatedAnnual report
「In the innovation business, the company received a lump-sum payment relating to the licensing of rights in connection with entering into a joint development agreement with SCSK Corporation in the previous fiscal year, and recognized the amount allocated monthly over the license period as revenue in the first quarter.」
The receipt and allocation over time of consideration for rights licensed under the joint development agreement with SCSK are restated as events occurring in prior fiscal years and the first quarter. - FY2019-Q2RestatedAnnual report
「In the innovation business, the company received a lump-sum payment relating to the licensing of rights in connection with entering into a joint development agreement with SCSK Corporation in the previous fiscal year, and recognized the amount allocated monthly over the license period as revenue in the first quarter.」
The receipt and recognition as revenue of consideration for rights licensed under the joint development agreement with SCSK are restated as events occurring in prior fiscal years and the first quarter. - FY2019-Q1RestatedAnnual report
「In the innovation business, in connection with entering into a joint development agreement with SCSK Corporation, the company received a lump-sum payment relating to the licensing of rights and recognized the amount allocated monthly over the license period as revenue.」
The company continues to recognize as revenue the consideration for rights licensed under the joint development agreement with SCSK. - FY2018AdvancedAnnual report
「In addition, in the fiscal year under review, in connection with entering into a joint development agreement with SCSK Corporation, the company received a lump-sum payment relating to the licensing of rights and recognized the amount allocated monthly over the license period as revenue. Revenue was ¥83 million, while the segment loss was ¥85 million due to research and development expenses and other costs.」
Following the agreement with SCSK, the consideration for the license was recognized as revenue, and the joint development and sales alliance relating to AI registers was reflected in accounting revenue. - FY2018-Q3First statedAnnual report
「The company has entered into an agreement with SCSK Corporation covering the joint development of register products using artificial intelligence technology developed by the company and the granting of sales rights.」
As of 27 October 2017, the company had entered into an agreement covering the joint development of AI technology, a lump-sum payment as consideration, and the grant of sales rights for register products.